Latest News

In the first large-scale study of its kind, researchers at Kaiser Permanente and the University of California San Francisco found that rates of dementia risk vary across racial and ethnic groups.
In spite of the Affordable Care Act's contraceptive coverage guarantee, there have been some obstacles in ensuring that privately insured women do not encounter out-of-pocket cost.
This week in managed care the top stories included President Obama's final budget plan, value-based deals made for Novartis' new heart drug, and a look at the strides made in immuno-oncology.
Healthcare integrated with housing support for homeless medically vulnerable lowers costs without affecting quality of care.
A study published in Cancer Epidemiology, Biomarkers & Prevention has identified geographic and ethnic factors as an important determinant of vaccinating against the human papillomavirus.
Every year, health policy wonks get into the loving spirit of Valentine’s Day with poetry, puns, and more on Twitter using the popular hashtag #HealthPolicyValentines. We round up some of the best.
From fighting cancer to the nation's heroin epidemic, there are items in President Obama's final budget that likely have bipartisan support even if the budget as a whole was panned on arrival.
Patients with advanced kidney cancer in the UK now have access to nivolumab through an early access scheme.
The results amplify earlier work at UAB that showed verapamil reversed type 1 diabetes in mice. A clinical trial involving the drug in recently diagnosed patients with type 1 disease is still enrolling participants.
What we're reading, February 12, 2016: the former Kentucky governor is looking to block the current governor's plans to dismantle Kynect; Senator Orrin Hatch speaks out against Medicare negotiation of drug prices; and the link between Zika and microcephaly is growing stronger.
Findings reveal an obvious area for improvement in population health.
The report on the Traditional Foods Project is part of CDC supplement on reducing healthcare disparities.
A study published in JAMA Oncology found that the knowledge of genetic risk influenced surgical treatment decisions in women younger than 40 years who were diagnosed with breast cancer.
What we're reading, February 11, 2016: Plaintiffs lose their case against cigarette manufacturer; the politics behind providing care for those infected with Zika; and of course, prescription drug prices.

From the Journals

Carfilzomib, a proteasome inhibitor, has been approved by the FDA for use in combination with dexamethasone or lenalidomide, in patients with relapsed/refractory multiple myeloma who have previously received 1 to 3 lines of therapy.
A summary of updated breast cancer screening guidelines, MEDPAC recommendations for 340B, and disparity in survival of young patients with Hodgkin lymphoma.
At the annual JP Morgan Healthcare Conference, Patrick Soon-Shiong, MD, introduced Cancer MoonShot, his vision for a coalition to improve cancer outcomes. His claims on federal support for the project, however, stirred some controversy.
While the number and diversity of immunologically-based anticancer agents have increased dramatically, a number of challenging questions persist: sequencing with existing regimens, selection of best responders, cost, and patient access.
The cost issues with immuno-oncology agents are real, but so is the value that they bring to the table. How can we improve access to these agents at a reasonable cost?
An overview of patient assistance programs at Smilow Cancer Hospital at Yale-New Haven, including their innovative hospital-based explanation of benefits form, which can eliminate patient responsibilities and help expedite the turnaround times for payment processing with copay assistance.
Ensuring rapid, appropriate, and sustainable access to immuno-oncology therapies for patients in Europe: what role can policies play?
To address the nationwide concern of costly immunotherapy agents, this article features health system inpatient and outpatient strategies that can help mitigate their costs.
Advances made in the field of immuno-oncology (I-O) in 2015 have greatly expanded our understanding of I-O and added more complexity to its value assessment.
x-button
Featured Content
Feature
Diabetes Compendium
Oncology Compendium
COPD Compendium
Reimbursement Compendium
HF Compendium

Most Popular

AJMC Strategic Alliance

$vacMongoViewPlus$